Guides, comparisons, and research summaries for adults looking at ibogaine, ayahuasca, alcohol use disorder, evidence, and safety with a clear view of uncertainty.
This is information work—not a treatment plan, medical clearance, or promise of an outcome.
Open Field 77 is an independent resource on alcohol use disorder and psychedelic risk. The work here is built for careful reading: what is known, what is not known, what can be confused, and what deserves a safety pause.
Alcohol use disorder is a recognized health condition, and established care can include behavioral therapies, medications, and support options; the National Institute on Alcohol Abuse and Alcoholism’s overview of alcohol use disorder describes the condition and its treatment context. These pages do not present ibogaine or ayahuasca as established treatment.
For the broader frame that informs these pages, return to the main guide to alcohol use and psychedelic risk or see how Open Field 77 approaches evidence and uncertainty.
Each offering is informational: a way to identify distinctions, evidence limits, terminology, and risks without turning complex decisions into a simple verdict.
Side-by-side explainers distinguish ibogaine from ayahuasca by substance, setting, stated purpose, research status, and safety concerns. The aim is to make comparison possible without implying that either substance is an established answer to alcoholism.
Practical reading frameworks surface questions about evidence, screening, medication interactions, cardiac concerns, expectations, and setting. They support careful discussion and do not replace individualized medical assessment.
Definitions help separate common terms that may be used loosely in discussion. For example, ibogaine and ayahuasca refer to different substances and traditions, so treating them as interchangeable obscures important context.
Research summaries identify what a study can and cannot show, alongside safety-focused reading. For additional context on ibogaine information and considerations, readers may consult ibogaine-clinic.com’s ibogaine overview while keeping independent evaluation central.
Ibogaine and ayahuasca are frequently discussed alongside personal accounts, legal variation, ceremony, treatment language, and recovery hopes. Those threads should not be collapsed into a clinical conclusion. Our summaries mark the gap between anecdote, preliminary research, and established care.
Safety context matters especially where cardiac risk, neurological concerns, mental health history, medications, or substance withdrawal may be relevant. The FDA’s information on psychedelic drugs underscores the importance of regulated research and the limits of assuming investigational substances are proven care.
“A comparison is useful when it makes uncertainty easier to see—not easier to ignore.”
No. Open Field 77 is an independent information resource. It does not provide medical assessment, treatment, referrals, or clinical recommendations. The material is intended to support clearer understanding, not to substitute for qualified care.
A comparison can help distinguish substances, settings, evidence limits, and safety concerns without treating either as established care for alcohol use disorder. The dedicated ibogaine and ayahuasca comparison develops that distinction in more detail.
It means retaining risk, uncertainty, contraindications, and context in the same frame as possible interest or reported benefit. For a focused overview, see the site’s cardio, neuro, and drug-interaction considerations.
The about page explains the mission, scope, and evidence-first approach behind Open Field 77. It also clarifies why the site avoids presenting these substances as established treatment.